Ipsen SA (IPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH15876FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ipsen SA (IPN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in few countries. It main research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Apr 01,2021: Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
Feb 11,2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20,2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01,2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22,2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ipsen SA – Key Facts
Ipsen SA – Key Employees
Ipsen SA – Key Employee Biographies
Ipsen SA – Major Products and Services
Ipsen SA – History
Ipsen SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Other Revenues
Performance
Business Segment: Specialty Care
Overview
Performance
Geographical Segment: Major Western European Countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA – Corporate Strategy
Ipsen SA – SWOT Analysis
SWOT Analysis – Overview
Ipsen SA – Strengths
Ipsen SA – Weaknesses
Ipsen SA – Opportunities
Ipsen SA – Threats
Ipsen SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021
Jan 20, 2021: Ipsen appoints Gwenan White as executive Vice President, Communications and Public Affairs
Dec 01, 2020: Ipsen highlights new strategic priorities and provides mid-term financial outlook
Oct 22, 2020: Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Oct 05, 2020: FAS RUSSIA: Ipsen unreasonably refused Biotek to conclude contract for medicine supply
Sep 25, 2020: Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
Jul 30, 2020: Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
Jul 01, 2020: David Loew joins Ipsen as CEO
Jun 08, 2020: Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society
May 29, 2020: Ipsen appoints David Loew as chief executive officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ipsen SA (IPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maastricht University:医療機器:M&Aディール及び事業提携情報
    Summary Maastricht University (MU) is an educational service provider that offers academic programs such as bachelor degree, master and doctoral programs. The university offers postgraduate research degrees in various subjects for a range of research needs and interests. It offers programs through i …
  • China Shipbuilding Industry Corp:企業の戦略・SWOT・財務情報
    China Shipbuilding Industry Corp - Strategy, SWOT and Corporate Finance Report Summary China Shipbuilding Industry Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Fujirebio Europe NV:企業の戦略的SWOT分析
    Fujirebio Europe NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Debiopharm International SA:医療機器:M&Aディール及び事業提携情報
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Trican Well Service Ltd. (TCW)-石油・ガス分野:企業M&A・提携分析
    Summary Trican Well Service Ltd. (Trican) is an oilfield services company, which provides a range of specialized products, equipment, services and technology for use in the drilling, completion, stimulation and reworking of oil and gas wells. Its specialized services comprise fracturing, cementing, …
  • PPG Industries Inc (PPG):企業の財務・戦略的SWOT分析
    PPG Industries Inc (PPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AIG Europe Limited:企業の戦略・SWOT・財務情報
    AIG Europe Limited - Strategy, SWOT and Corporate Finance Report Summary AIG Europe Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Suncor Energy Inc.:企業の戦略・SWOT・財務分析
    Suncor Energy Inc. - Strategy, SWOT and Corporate Finance Report Summary Suncor Energy Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sonivate Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sonivate Medical Inc (Sonivate Medical) is a medical device company that develops and manufactures diagnostic imaging technologies. The company offers dual-plane ultrasound probe, a finger-mounted ultrasound probe that leverages innate human hand eye coordination, which with any ultrasound s …
  • New Hope Corp Ltd:企業の戦略・SWOT・財務情報
    New Hope Corp Ltd - Strategy, SWOT and Corporate Finance Report Summary New Hope Corp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Tec-Masters Inc:企業の戦略・SWOT・財務情報
    Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report Summary Tec-Masters Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GI Dynamics Inc (GID)-製薬・医療分野:企業M&A・提携分析
    Summary GI Dynamics Inc (GI Dynamics) is a medical device company that develops and commercializes endoscopy instruments. The company’s product includes EndoBarrier, an endoscopically delivered device therapy that is designed to mimic the mechanisms of metabolic surgery- without altering the anatomy …
  • Sojitz Corp (2768):電力:M&Aディール及び事業提携情報
    Summary Sojitz Corp (Sojitz) is a diversified general trading group. The group through its subsidiaries and affiliates holds interest in machinery; energy and metals; chemicals and functional materials; and consumer lifestyle businesses. It distributes automobiles and aircraft; develops power projec …
  • Ironwood Pharmaceuticals Inc (IRWD):製薬・医療:M&Aディール及び事業提携情報
    Summary Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company's major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with c …
  • Bio-Reference Laboratories Inc:企業の戦略的SWOT分析
    Bio-Reference Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Sectra AB (SECT B):医療機器:M&Aディール及び事業提携情報
    Summary Sectra AB (Sectra) develops and sells technologies for medical systems and secure communication systems. Its operations are concentrated on two major sectors: Image IT Solutions and Secure Communications. The company’s subsidiary, Sectra Imaging IT Solutions AB, offers medical information te …
  • Euromoney Institutional Investor PLC (ERM):企業の財務・戦略的SWOT分析
    Euromoney Institutional Investor PLC (ERM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Sensorion SA (ALSEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • Richter Gedeon Nyrt (RICHTER):企業の財務・戦略的SWOT分析
    Richter Gedeon Nyrt (RICHTER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆